Fax: (215) 503-8755
Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma
A Two-Cohort Study
Article first published online: 11 JAN 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 5, pages 1305–1314, 1 March 2010
How to Cite
Carr, B. I., Kondragunta, V., Buch, S. C. and Branch, R. A. (2010), Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma. Cancer, 116: 1305–1314. doi: 10.1002/cncr.24884
- Issue published online: 18 FEB 2010
- Article first published online: 11 JAN 2010
- Manuscript Accepted: 8 JUL 2009
- Manuscript Revised: 6 JUL 2009
- Manuscript Received: 29 MAY 2009
- hepatocellular carcinoma;
- internal radiation
Intrahepatic arterial yttrium 90 (90Y) microspheres have been proposed as a less toxic, less invasive therapeutic option to transhepatic arterial chemoembolization (TACE) for patients with surgically unresectable hepatocellular carcinoma (HCC). TACE has demonstrated the ability to prolong survival. However, long-term survival remains uncertain.
In a 2-cohort experience in the treatment of North American patients who had advanced, unresectable, biopsy-proven HCC, 691 patients received repetitive, cisplatin-based chemoembolization; and a separate cohort of 99 patients who had similar treatment criteria received a planned, single dose of 90Y. Over the study period, an additional 142 patients were followed without treatment (total, 932 patients).
Overall survival was slightly better in the 90Y group compared with the TACE group (median survival, 11.5 months vs 8.5 months). However, the selection criteria indicated a small but significant bias toward milder disease in the 90Y group. By using stratification into a 3-tier model with patients dichotomized according to bilirubin levels <1.5 mg/dL, the absence of portal vein thrombosis (PVT), and low α-fetoprotein plasma levels (<25 U/dL), an analysis of survival in clinical subgroups indicated that the 2 treatments resulted in similar survival. In addition, patients who had PVT or high α-fetoprotein levels also had similar survival in both treatment groups.
Given the current evidence of therapeutic equivalence in survival, 90Y and TACE appeared to be equivalent regional therapies for patients with unresectable, nonmetastatic HCC. Cancer 2010. © 2010 American Cancer Society.